1. Successful Use of Bortezomib in an Adolescent with Refractory TTP
- Author
-
Junaid Ahmad Wali, Brian M. Quigley, and Beverly Schaefer
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
With increasing early and upfront use of rituximab and caplacizumab in the modern management of immune-mediated thrombotic thrombocytopenic purpura (iTTP), the risk of refractory disease is expected to decline. However, despite the use of adequate initial therapy, a small subset of patients develop a refractory disease which is difficult to manage. Bortezomib has come to be known as a safe and effective treatment option for refractory iTTP, but its use in children is limited. Here, we describe the case of an adolescent patient with refractory iTTP who had a satisfactory and sustained response to the use of bortezomib.
- Published
- 2023
- Full Text
- View/download PDF